FDA flags unapproved retatrutide sold for weight loss
The still-investigational Eli Lilly triple agonist is being marketed outside approved channels, drawing regulator attention.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 2 17:41 ETSource: bworldonline.com
The wire
- 01BusinessWorld reports FDA concern over unapproved GLP-1 products, including retatrutide, being sold and used for weight loss.
- 02Retatrutide has no marketing approval anywhere, so any supply reaching patients comes from compounders or gray-market research-chemical sellers.
- 03Details of any formal FDA action were not laid out; readers should watch for warning letters or import alerts naming specific sellers.
From the source
Read at bworldonline.comfda concerns unapproved glp-1 drugs retatrutide weight loss
